Monoclonal Antibodies to Herpes Simplex Virus Type 1 Proteins, Including the Immediate-early Protein ICP 4
Overview
Authors
Affiliations
Monoclonal antibodies were prepared against herpes simplex virus type 1 (strain 14012) by two immunization procedures. Procedure A utilized infectious virus propagated in mouse cells, and procedure B utilized mouse cells infected with herpes simplex virus in the presence of cycloheximide and harvested 1 h after removal of the inhibitor. A total of 52 monoclonal antibodies were obtained against 10 herpes simplex virus proteins, including four glycosylated proteins (a 110,000-molecular-weight protein, gB, gC, and gD) and six nonglycosylated proteins (a 68,000-molecular-weight protein, ICP 9, ICP 8, ICP 6, ICP 5, and the immediate-early ICP 4). The antibodies were assayed against herpes simplex virus types 1 and 2 by sodium dodecyl sulfate-polyacrylamide gel electrophoresis of radioimmunoprecipitates, immunofluorescence, and neutralization. Using the reagents prepared, we concluded that the 110,000-molecular-weight protein, gD, ICP 9, ICP 9, ICP 6, and the 68,000-molecular-weight protein express both type-specific and cross-reactive antigenic determinants. In contrast, nine antibodies against gB all cross-reacted with herpes simplex virus type 2, whereas eight antibodies to gC all reacted type specifically.
Roberts A, Orr A, Iliev V, Orr L, McFarlane S, Yang Z bioRxiv. 2024; .
PMID: 39185184 PMC: 11343217. DOI: 10.1101/2024.08.15.608064.
Sp1 facilitates continued HSV-1 gene expression in the absence of key viral transactivators.
Sodroski C, Oh H, Chou S, Knipe D mBio. 2024; 15(3):e0347923.
PMID: 38349188 PMC: 10936440. DOI: 10.1128/mbio.03479-23.
Sodroski C, Knipe D Proc Natl Acad Sci U S A. 2023; 120(45):e2310996120.
PMID: 37883416 PMC: 10636318. DOI: 10.1073/pnas.2310996120.
Herpes simplex virus infected cell protein 8 is required for viral inhibition of the cGAS pathway.
Broekema N, Mertens M, Angelova M, Orzalli M, Oh H, Knipe D Virology. 2023; 585:34-41.
PMID: 37271042 PMC: 10526635. DOI: 10.1016/j.virol.2023.05.002.
Innovative retargeted oncolytic herpesvirus against nectin4-positive cancers.
Vannini A, Parenti F, Forghieri C, Barboni C, Zaghini A, Campadelli-Fiume G Front Mol Biosci. 2023; 10:1149973.
PMID: 37251078 PMC: 10213976. DOI: 10.3389/fmolb.2023.1149973.